Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results and Operational Highlights August 26, 2021
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides August 23, 2021
Ceapro Inc. Expands Collaboration with Montreal Heart Institute (MHI) with New Clinical Study Evaluating Flagship Product, Avenanthramide August 11, 2021
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as a Cholesterol-Lowering Agent May 26, 2021
Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights April 22, 2021
Ceapro Inc. Announces Successful Completion of Collaborative Research and Development Program with University of Alberta April 8, 2021
